Clinical & scientific operations case studies

Maximising patient recruitment and retention, and expanding access to diverse patient populations.

We work with you to develop strategic, flexible approaches that leverage clinical informatics, state-of-the-art technologies, and our global reach to make data-driven decisions for every study.

Examining approved adult drugs for kidney disease in children

A pharmaceutical company faced significant delays in its pediatric program, particularly in recruiting younger age groups, putting the study at risk. After missing multiple deadlines, the sponsor turned to ICON’s Centre for Paediatric Clinical Development for a strategic review, which resolved recruitment challenges and aligned the program with U.S. and European regulatory guidance.

FSP for a mid-sized device company

A mid-sized medical device company, required a smooth transition from using a staffing company alongside a full-service model, to an FSP model.

Driving high quality in global clinical drug development

A China-based biotech required an FSP model to grow team to 130 resources and increase retention to 85% in a highly competitive market.

Elevating Biopharma R&D

A biopharma partner required support with an FSP model across multiple service areas, seamlessly integrated with an existing FSO partnership.

Transforming a partnership into a blended model

A 10-year existing FSO partnership was expanded to incorporate a blended model to aid sourcing niche roles across multiple geographies whilst the sponsor maintained greater control of key areas.

Integrating safety and efficacy data for submission analysis

A top-tier pharma company partnered with ICON to harmonize legacy data from 11 oncology studies into CDISC standards, resolving non-compliance issues.

Collaborative approach to advance early phase breast cancer research

A biopharma company partnered with ICON to conduct a phase 1/2 study on breast cancer, overcoming challenges related to regulatory compliance, tight timelines, and data integrity through strategic statistical analysis.

Streamlining non-CDISC decentralised trial data analysis and reporting

A pharma company conducted a phase 2 DCT, and faced challenges with non-standardised data and shifting priorities, which ICON addressed by collaborating with the data vendor to standardize data transfers and using a metadata-driven approach to streamline statistical analysis.